Error! Reference source not found. I. SUMMARY OF PRODUCT CHARACTERISTICS

Similar documents
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. Medicinal product no longer authorised

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/18

SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

= 0.5 mg. In vitro toxin neutralisation test based on haemolysis of sheep erythrocytes. For a full list of excipients, see section 6.1.

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

[Version 7.2, 12/2008] ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS. NUFLOR 300 mg/ml solution for injection for cattle and sheep

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Summary of Product Characteristics

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS VIRBAGEN OMEGA - EN 1

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/12

Summary of Product Characteristics

Summary of Product Characteristics

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

For the treatment of infections caused by a wide range of Gram-positive and Gramnegative pathogenic bacteria including:

B. PACKAGE LEAFLET 1

SUMMARY OF PRODUCT CHARACTERISTICS. Bottle of powder: Active substance: ceftiofur sodium mg equivalent to ceftiofur...

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. Medicinal product no longer authorised

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

LABELLING AND PACKAGE LEAFLET

SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS. Pentoject, Pentobarbitone Sodium 200 mg/ml Solution for Injection

SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

BOX 1. NAME OF THE VETERINARY MEDICINAL PRODUCT. Hymatil 300 mg/ml solution for injection for cattle and sheep Tilmicosin

MARBOCYL 10% SUMMARY OF PRODUCT CHARACTERISTICS

Ubroseal Dry Cow 2.6 g intramammary suspension for cattle

Health Products Regulatory Authority

SUMMARY OF PRODUCT CHARACTERISTICS

[Version 8.1,01/2017] ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Summary of Product Characteristics

Summary of Product Characteristics

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS. Procaine penicillin Dihydrostreptomycin Sulfate

SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Summary of Product Characteristics

Irish Medicines Board

LUTEOSYL(d)-Cloprostenol mg/ml Solution for injection for cattle and pigs

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS. Euthasol vet. 400 mg/ml, solution for injection (AT, BE, DK, EE, EL, FI, IE, IS, LT, LU, LV, NO, PL, RO SE, UK)

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Paul-Ehrlich-Institut Bundesinstitut für Impfstoffe und biomedizinische Arzneimittel Federal Institute for Vaccines and Biomedicines

ANNEX III LABELLING AND PACKAGE LEAFLET

SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Summary of Product Characteristics

SUMMARY OF PRODUCT CHARACTERISTICS. 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Emdocam 20 mg/ml solution for injection for cattle, pigs and horses

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

4.5. Special precautions for use Special precautions to be taken by person administering the veterinary medicinal product to animals

Summary of Product Characteristics

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

Fluralaner (mg) for small cats kg for medium-sized cats > kg for large cats > kg 1.

LABELLING AND PACKAGE LEAFLET A. LABELLING

Ear drops suspension. A smooth, uniform, white to off-white viscous suspension.

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Irish Medicines Board

Summary of Product Characteristics

Summary of Product Characteristics

[Version 8, 10/2012] SUMMARY OF PRODUCT CHARACTERISTICS

Summary of Product Characteristics

SUMMARY OF PRODUCT CHARACTERISTICS 1.B.1 SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS. Cephacare flavour 50 mg tablets for cats and dogs. Excipients: For a full list of excipients, see section 6.1.

SUMMARY of PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

PART IB1 SUMMARY OF PRODUCT CHARACTERISTICS OCTACILLIN

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

MARBOCYL FD SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Withdrawal period: 93 days Milk: Not authorised for use in animals producing milk for human consumption.

SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/25

Day 90 Labelling, PL LABELLING AND PACKAGE LEAFLET

Summary of Product Characteristics

Summary of Product Characteristics

Summary of product characteristics As per Annex C. SUMMARY OF PRODUCT CHARACTERISTICS Doc. No. SPC/71108 Ver.1

SUMMARY OF PRODUCT CHARACTERISTICS

Vetoquinol/DOLPAC Small dogs/european Renewal June 2011 SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS. 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Vetrisulf powder for oral solution for chickens, turkeys and geese

SUMMARY OF PRODUCT CHARACTERISTICS

Transcription:

PRODUCTNAME NOBIVAC RABIES 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Nobivac Rabies 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active components: Rabies strain Pasteur RIV; at least 2 I.U. per dose Preservative: Thiomersal 0.01% 3. PHARMACEUTICAL FORM Suspension for injection. 4. CLINICAL PARTICULARS 4.1 Target species Dogs, cats, cattle, sheep, goats, foxes, ferrets and horses. 4.2 Indications for use specifying the target species (if appropriate) For the active immunisation of healthy dogs, cats, cattle, sheep, goats, ferrets, foxes and horses, and in principle all healthy mammals against rabies. 4.3 Contraindications None 4.4 Special warnings None 4.5 Special precautions for use Allow the vaccine to reach ambient temperature (15-25 C) before use. Use sterile injection equipment. Shake before and during use. Special precautions for use in animals Vaccinate healthy animals only. Special precautions to be taken by the person administering the veterinary medicinal product to animals None 4.6 Adverse reactions (frequency and seriousness) After subcutaneous administration occasionally a transient palpable nodule may occur at the site of injection. Generalised hypersensitivity reactions following administration may occasionally occur. 4.7 Use during pregnancy and lactation Can be used during pregnancy in dogs.

PRODUCTNAME NOBIVAC RABIES 4.8 Interaction with other medicinal products and other forms of interaction Nobivac Rabies can be used to reconstitute the freeze-dried canine vaccines of the Nobivac series. Nobivac Rabies can be administered with the Nobivac leptospirosis vaccines at the same time but at a different administration site. No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product except the products mentioned above. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis. 4.9 Amounts to be administered and administration route 1 ml by subcutaneous or intramuscular injection. 4.10 Overdose (symptoms, emergency procedures, antidotes) (if necessary) After subcutaneous administration occasionally a transient palpable nodule may occur at the site of injection. 4.11 Withdrawal period(s) Not applicable. 5. IMMUNOLOGICAL PROPERTIES Inactivated viral vaccine ATC vet code for dogs: QI07AA02 Induction of active immunity against rabies. 6. PHARMACEUTICAL PARTICULARS 6.1 Incompatibilities Do not mix with any other veterinary medicinal product except the vaccines of the Nobivac series mentioned in section 4.8. 6.2 Shelf life At least 4 years at 2-8 C. Broached vials of the 10-dose presentation should be used within one working day. 6.3 Special precautions for storage Store at 2-8 C. Protect from light. 6.4 Nature and composition of immediate packaging Glass vials closed with a rubber stopper, and sealed with an aluminium cap. 6.5 Special precautions for the disposal of unused medicinal product or waste materials derived from the use of such products Dispose of waste material by boiling, incineration or immersion in an appropriate disinfectant approved for use by the competent authorities. 7. MARKETING AUTHORISATION HOLDER Intervet International B.V. Wim de Körverstraat 35 Boxmeer The Netherlands

Annex A. Labelling ANNEX A. LABELLING PARTICULARS TO APPEAR ON THE OUTER PACKAGE 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Nobivac Rabies 2. PACKAGE SIZE 10x1 dose 50x1 dose 10x10 doses 3. INDICATION(S) Inactivated vaccine containing 2 I.U. rabies virus strain Pasteur RIV per dose. Preservative: Thiomersal 0.01%. 4. EXPIRY DATE Expiry {month/year} Mfg.date {month/year} 5. SPECIAL STORAGE CONDITIONS Store at 2-8 C. Protect from light. 6. THE WORDS FOR ANIMAL TREATMENT ONLY AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, if applicable For animal treatment only. 7. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER Intervet International B.V. Boxmeer The Netherlands 8. MARKETING AUTHORISATION NUMBER(S) 9. MANUFACTURER S BATCH NUMBER Batch {number}

Annex A. Labelling MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Nobivac Rabies 2. INDICATION(S) Inactivated rabies vaccine 3. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES 1 dose 10 doses 4. SPECIAL STORAGE CONDITIONS Store between 2-8 C. Protect from light. 5. BATCH NUMBER Batch {number} 6. EXPIRY DATE Expiry {month/year} Mfg.date {month/year} 7. THE WORDS FOR ANIMAL TREATMENT ONLY For animal treatment only.

Annex B. Package leaflet ANNEX B. PACKAGE LEAFLET Nobivac Rabies FOR ANIMAL TREATMENT ONLY DESCRIPTION This vaccine contains an inactivated culture of rabies virus, cloned out of strain Pasteur RIV with a potency of 2 I.U. The virus is grown on the BHK-21 clone CT cell line and inactivated with beta-propiolactone. It is presented as an aluminium phosphate adsorbed vaccine. COMPOSITION Active components: Rabies strain Pasteur RIV: at least 2 I.U. per dose. Preservative: Thiomersal 0.01% INDICATION For the active immunisation of healthy dogs, cats, cattle, sheep, goats, ferrets, foxes and horses, and in principle all healthy mammals against rabies. DOSAGE AND ADMINISTRATION 1 ml by subcutaneous or intramuscular injection. RECOMMENDED VACCINATION PROGRAMME Primary vaccination at an age of more than Dogs/Cats Cattle/Horses Ferrets 3 months* 6 months* 3 months* Revaccination every 3 years** 2 years** 1 year** Route of administration i.m. or s.c. i.m. s.c. * Primary vaccination can be administered at an earlier age, but then a repeat vaccination must be given at the age of 3 or 6 months depending on the species. ** Recommended revaccination interval is based upon results from challenge experiments. Local regulations in force may require earlier revaccination. Results from serological investigations indicate that vaccination of sheep, goats, and foxes provides protection for at least one year. VACCINATION REACTIONS After subcutaneous administration occasionally a transient palpable nodule may occur at the site of injection.

Annex B. Package leaflet NOTE - Vaccinate healthy animals only. - Generalised hypersensitivity reactions following administration may occasionally occur. - Allow the vaccine to reach ambient temperature (15-25 C) before use. - Use sterile injection equipment. - Shake before and during use. - Nobivac Rabies can be used to reconstitute the freeze-dried canine vaccines of the Nobivac series. - Nobivac Rabies can be administered with the Nobivac leptospirosis vaccines at the same time but at a different administration site. - Keep out of the reach and sight of children. IMMUNITY In dogs, peak antibody titres have been demonstrated to occur by 3 weeks after vaccination. STORAGE Store at 2-8 C. For the 10 dose presentation, broached vials should be used within one working day. PRECAUTIONS FOR DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIAL No special precautions are required. Dispose by the appropriate channels. PACKING Vials containing 1 or 10 doses. Product of: INTERVET INTERNATIONAL B.V. BOXMEER THE NETHERLANDS